Table 1.
Patients, N | 50 |
Median age, y (range) | 64 (18–81) |
Gender | 13 F / 37 M |
WHO classification | |
Refractory anemia | 7 |
Refractory anemia with ringed sideroblasts | 4 |
Refractory cytopenia with multilineage dysplasia | 6 |
Refractory cytopenia with multilineage dysplasia and ringed sideroblasts |
2 |
Refractory anemia with excess blasts 1 | 6 |
Refractory anemia with excess blasts 2 | 12 |
MDS-AML | 6 |
Chronic myelomonocytic leukemia | 7 |
IPSS score | |
Low | 6 |
Intermediate-1 | 17 |
Intermediate-2 | 13 |
High | 13 |
Not available | 1 |
Previous Treatment | |
Growth Factor | 23 |
Azacitidine | 10 |
Anthi-thymocyte globulin | 3 |
Thalidomide / lenalidomide | 8 |
Cytotoxic Chemotherapy | 6 |